Hims & Hers Health (NYSE:HIMS) Now Covered by JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. started coverage on shares of Hims & Hers Health (NYSE:HIMS) in a research note issued on Friday. The brokerage set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 18.70% from the stock’s previous close.

A number of other research analysts have also weighed in on HIMS. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and raised their target price for the stock from $13.25 to $24.00 in a research note on Tuesday, March 10th. Truist Financial reaffirmed a “hold” rating and set a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a report on Tuesday, February 24th. Evercore set a $24.00 price objective on Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Leerink Partners upped their price objective on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research note on Monday, March 16th. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $32.53.

Hims & Hers Health Stock Up 1.6%

Shares of NYSE HIMS opened at $29.49 on Friday. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The stock has a market cap of $6.72 billion, a P/E ratio of 57.82, a P/E/G ratio of 2.75 and a beta of 2.32. The firm has a 50 day moving average price of $20.70 and a 200 day moving average price of $31.71.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. Analysts expect that Hims & Hers Health will post 0.61 EPS for the current year.

Insider Activity

In related news, insider Irene Becklund sold 5,529 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the transaction, the insider directly owned 8,752 shares of the company’s stock, valued at $216,086.88. This trade represents a 38.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20. Following the transaction, the chief financial officer directly owned 262,954 shares in the company, valued at approximately $7,878,101.84. This represents a 6.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 204,857 shares of company stock worth $5,285,706. 13.71% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the company. Pathway Capital Management LP purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $6,766,000. Steadview Capital Management LLC grew its position in shares of Hims & Hers Health by 80.0% in the 3rd quarter. Steadview Capital Management LLC now owns 701,845 shares of the company’s stock worth $39,809,000 after buying an additional 311,845 shares during the last quarter. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 30.8% during the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares during the period. BIT Capital GmbH raised its holdings in shares of Hims & Hers Health by 73.8% during the third quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after acquiring an additional 938,728 shares in the last quarter. Finally, State of Michigan Retirement System lifted its stake in Hims & Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after acquiring an additional 678,600 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Expanded Eli Lilly tie‑up — HIMS said clinicians on its platform can now connect patients to Eli Lilly self‑pay pricing and fulfillment (Zepbound vials, KwikPen, Foundayo via LillyDirect), driving a near‑term revenue pathway for weight‑loss prescriptions and sparking a prior ~7% jump in the stock. Article Title
• Positive Sentiment: New product expansion into menopause care — HIMS is adding perimenopause/menopause treatment options (including estrogen patches) to its telehealth platform to capture rising U.S. demand, expanding addressable market and recurring care use cases. Article Title
• Positive Sentiment: Regulatory/pipeline momentum — An FDA Pharmacy Compounding Advisory Committee review of several peptides has been scheduled (July), which market participants view as a potential tailwind for HIMS’ peptide ambitions and helped recent sentiment. Article Title
• Neutral Sentiment: Analyst update — Bank of America raised its price target from $30 to $32 but kept a “neutral” rating, signaling modest upside without changing conviction. Article Title
• Neutral Sentiment: Independent Rx fills & sector flows — News roundups note increased independent Rx fills and broad interest in telehealth/weight‑loss plays; sector rotation and flow can amplify HIMS’ volatility even when company‑specific news is mixed. Article Title
• Negative Sentiment: Insider selling — CFO Oluyemi Okupe sold 19,645 shares and director/insider Soleil Boughton sold 9,463 shares under 10b5‑1 plans; sizeable insider exits are pressuring near‑term sentiment despite being pre‑arranged. Okupe SEC Filing Boughton SEC Filing
• Negative Sentiment: Competitive risk — Large entrants (notably Amazon’s GLP‑1/weight‑loss efforts) and other well‑capitalized competitors raise concerns about pricing pressure and customer share loss in the high‑value weight‑loss channel. Article Title

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.